1 unchanged sentence
During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
−Removed: On May 6, 2026, we agreed to issue warrants to purchase 100,000 shares of common stock with an exercise price of $2.48 per share to an entity providing consulting services, which warrants will vest in 12 equal monthly installments over one year, subject to the entity's continued provision of consulting services to the Company.
−Removed: The warrant was issued pursuant to the exemption from the registration requirements of the Securities Act of 1933 available under Section 4 (a)( 2 ) thereunder.
+Added: On August 10, 2026, Joy Yan resigned as a member of the Company's Board of Directors.
+Added: Yan's resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Amended and Restated Certificate of Incorporation of Moleculin Biotech, Inc.
11 unchanged sentences
(incorporated by reference to exhibit 3.1 of the Form 8-K filed December 17, 2021)
−Removed: Form of Series H Warrant (incorporated by reference to Exhibit 4.1 of the Form 8-K filed February 20, 2026)
−Removed: Form of Inducement Letter dated February 19, 2026 (incorporated by reference to Exhibit 10.1 of the Form 8-K filed February 20, 2026)
+Added: Form of Series I Common Stock Purchase Warrant used in August 2026 offering (incorporated by reference to exhibit 4.1 of the Form 8-K filed August 3, 2026)
+Added: Form of Pre-Funded Warrant used in August 2026 offering (incorporated by reference to exhibit 4.2 of the Form 8-K filed August 3, 2026)
+Added: Placement Agency Agreement dated July 31, 2026, by and between Moleculin Biotech, Inc.
+Added: and Roth Capital Partners, LLC (incorporated by reference to exhibit 1.1 of the Form 8-K filed August 3, 2026)
+Added: Form of Securities Purchase Agreement used in August 2026 offering (incorporated by reference to exhibit 10.1 of the Form 8-K filed August 3, 2026)
Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
16 unchanged sentences
MOLECULIN BIOTECH, INC.
+Added: August 13, 2026
/s/ Walter V.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 13, 2026
/s/ Jonathan P.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.